SH2scan: Scalable SH2 Domain Profiling to Reduce Off‑Target Risk and Accelerate SAR Decisions

Understanding how small molecules interact with their protein targets, and importantly, their off-targets, is one of the biggest challenges in drug discovery. This is especially true for Src Homology 2 (SH2) domains, a family of more than 120 protein–protein interaction modules involved in key signaling pathways across inflammation and oncology. Yet despite their therapeutic relevance, efforts to design selective SH2-targeting ligands have been slowed by a lack of scalable systems for evaluating binding specificity. Traditional tools often provide partial coverage, limited throughput, or only phosphopeptide-based interactions, leaving major gaps in understanding synthetic ligand behavior.

A new publication from Eurofins Discovery introduces SH2scan^®, a high throughput SH2 profiling platform designed to help discovery teams make faster, more confident decisions. By delivering broad, quantitative selectivity data early in a program, SH2scan enables clients to de risk lead series, prioritize the right compounds, and avoid costly late stage surprises.

What is SH2scan?

SH2scan is a plate-based competition binding assay that uses DNA-tagged SH2 domain constructs and phosphopeptide-coated magnetic beads to quantitatively measure ligand binding. By monitoring displacement of the tagged protein via qPCR, the system generates accurate dissociation constants (K_Ds) and selectivity fingerprints for each ligand–domain interaction.

The platform includes:

• 95 SH2 domain-containing constructs (covering 97 domains total)
• >80% coverage of canonical SH2 domains
• 7 mutant STAT constructs
• Optimized assay conditions ensuring true thermodynamic K_D values

This enables SH2scan to map how compounds bind across the entire target class, something not previously possible at scale.

The Study: Profiling 9 Synthetic SH2-Targeting Ligands

To demonstrate platform capabilities, the team profiled nine ligands from the literature, including:

• SRC family SH2 domain binders (Ac-pYEEIE-NH₂, caffeic acid-pYEEIE)
• Selective ligands for GRB2, SOCS2, STAT3, STAT5B, STAT6
• A PROTAC degrader (SD-36)

Each compound underwent:

• Primary screening at 10 μM
• Dose-response validation
• K_D extraction using the Hill equation

This produced a comprehensive selectivity map across the SH2 domain family.

Key Findings (What This Solves for You)

1. Comprehensive SH2 coverage reduces blind spots in selectivity profiling
   • With >80% coverage of canonical SH2 domains, SH2scan allows teams to evaluate ligand selectivity across the full target class – not just a subset
   • Client impact: Avoids hidden off-target liabilities that are often missed with limited panels, reducing downstream attrition risk
2. Profiling of inhibitors and degraders supports modern modality strategies
   • SH2scan successfully profiled both classical inhibitors and targeted degraders (e.g. SD-36)
   • Client impact: Enables consistent selectivity assessment across modalities, helping teams compare mechanism strategies (inhibition vs. degradation) and make better portfolio decisions
3. Early identification of off-target interactions enables proactive risk management
   • The platform uncovered previously unreported off-target interactions (e.g., STAT6 inhibitors binding SOCS4).
   • Client impact: Helps teams flag potential safety or efficacy risks at the screening stage, when mitigation is still fast and cost-effective, rather than during late preclinical or clinical phases.
4. Clear selectivity signatures accelerate SAR optimization
   • Even subtle structural changes (e.g., a single methyl group) resulted in distinct selectivity profiles.
   • Client impact: Provides actionable SAR insights that guide medicinal chemistry decisions, helping teams optimize potency without compromising selectivity.
5. Quantitative K_D values enable confident compound ranking
   • True thermodynamic K_D measurements support precise comparison across targets.
   • Client impact: Improves confidence in hit-to-lead progression by enabling data-driven prioritization of the best candidates.

Why Clients Use SH2scan

• De risk programs earlier with class wide off target visibility
• Accelerate SAR cycles with clear, actionable selectivity insights
• Prioritize compounds faster using quantitative K_D data
• Compare modalities (inhibitors vs. degraders) within a single platform
• Reduce costly late stage failures driven by unexpected selectivity issues

A New Chapter for SH2 Domain Research

SH2scan represents one of the most comprehensive solutions for profiling SH2 domain selectivity. By enabling broad, quantitative mapping of ligand interactions, SH2scan gives researchers the clarity they need to design more selective and effective molecules.

Explore how SH2scan can support your SH2-targeted program.

Read the full publication, discover our SH2 solutions, or contact our team to discuss your project.